These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 32063580)

  • 21. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
    Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L
    Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents.
    He G; Xie X; Siddik ZH
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1129-1140. PubMed ID: 32468080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
    Peirce SK; Findley HW
    Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
    Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
    J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation.
    Jiang M; Pabla N; Murphy RF; Yang T; Yin XM; Degenhardt K; White E; Dong Z
    J Biol Chem; 2007 Jan; 282(4):2636-45. PubMed ID: 17130128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nutlin-3a is a potential therapeutic for ewing sarcoma.
    Pishas KI; Al-Ejeh F; Zinonos I; Kumar R; Evdokiou A; Brown MP; Callen DF; Neilsen PM
    Clin Cancer Res; 2011 Feb; 17(3):494-504. PubMed ID: 21098696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes.
    Arva NC; Talbott KE; Okoro DR; Brekman A; Qiu WG; Bargonetti J
    Ethn Dis; 2008; 18(2 Suppl 2):S2-1-8. PubMed ID: 18646312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
    Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
    Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.
    Rinaldo C; Prodosmo A; Siepi F; Moncada A; Sacchi A; Selivanova G; Soddu S
    Cancer Res; 2009 Aug; 69(15):6241-8. PubMed ID: 19638586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
    de Lange J; Ly LV; Lodder K; Verlaan-de Vries M; Teunisse AF; Jager MJ; Jochemsen AG
    Oncogene; 2012 Mar; 31(9):1105-16. PubMed ID: 21765463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer.
    Roh JL; Park JY; Kim EH
    Apoptosis; 2014 Nov; 19(11):1594-602. PubMed ID: 25113507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.
    Carrillo AM; Hicks M; Khabele D; Eischen CM
    Mol Cancer Res; 2015 Aug; 13(8):1197-205. PubMed ID: 25964101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.
    He T; Guo J; Song H; Zhu H; Di X; Min H; Wang Y; Chen G; Dai W; Ma J; Sun X; Ma J
    Pathol Oncol Res; 2018 Jan; 24(1):75-81. PubMed ID: 28341911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
    Gamble LD; Kees UR; Tweddle DA; Lunec J
    Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.
    Hu B; Gilkes DM; Farooqi B; Sebti SM; Chen J
    J Biol Chem; 2006 Nov; 281(44):33030-5. PubMed ID: 16905541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3.
    Yang P; Chen W; Li X; Eilers G; He Q; Liu L; Wu Y; Wu Y; Yu W; Fletcher JA; Ou WB
    Oncotarget; 2016 May; 7(22):32652-63. PubMed ID: 27129163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
    Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
    Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
    Ray RM; Bhattacharya S; Johnson LR
    Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.
    Ohnstad HO; Paulsen EB; Noordhuis P; Berg M; Lothe RA; Vassilev LT; Myklebost O
    BMC Cancer; 2011 May; 11():211:1-11. PubMed ID: 21624110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.